Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Explore when to make changes to your spending plan and how to rebalance categories so you stay aligned with goals and cash flow.
23,566 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Over the past year, the more expensive GDX underperformed cheaper peers, costing investors tens of dollars per thousa...
As Portugal tightens incentives, a growing cohort of American retirees is quietly relocating to Greece, lured by tax ...
A large fund trimmed its IRADIMED stake while the company posted a record quarter, sparking discussion about growth, ...
A new, sizable stake in Cal-Maine Foods hints at investor conviction despite a halved income last quarter. This piece...
Federal Reserve officials weighed the strength of the labor market as January payrolls edge higher, creating a tense ...
Soleno's Q4 2025 earnings paint a picture of growth with new products and expanding margins. This guide breaks down t...
Geopolitical tremors surge as Iran will pick supreme leader within days. Traders weigh energy, currency, and consumer...
Trade Desk stock jumped on reports of a potential partnership with OpenAI, signaling fresh AI-driven upside for ad-te...
New high‑voltage lines aimed at powering AI data centers are igniting clashes from rural Pennsylvania to middle Ameri...
Rising tensions around Iran are lifting jet fuel costs and pressuring airline tickets globally. Here’s what travelers...
The NYC Council greenlights a 72-story Brooklyn tower with 1,263 units, a quarter permanently affordable. Constructio...